Recent Updates
Recently added Catalysts
SCYX

SCYNEXIS, Inc. to Present at the Cowen and Company 36th Annual Health Care Conference

Key Takeaway: JERSEY CITY, N.J., Feb. 29, 2016 (GLOBE NEWSWIRE) -- Drug development company SCYNEXIS, Inc. (NASDAQ:SCYX) today announced that the Company will present at the Cowen and Company 36th Annual Health Care Conference at the Boston Marriott Copley Place in Boston on Monday, March 7, 2

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+56%
120-day peak, hindsight
Typical move
12.1%
average across 3 past catalysts
Cash runway
~11 mo
Medium dilution risk
Lead asset
Ibrexafungerp
Phase 3 · Vulvovaginal Candidiasis

Full Press Release Details

JERSEY CITY, N.J., Feb. 29, 2016 (GLOBE NEWSWIRE) -- Drug development company SCYNEXIS, Inc. (NASDAQ:SCYX) today announced that the Company will present at the Cowen and Company 36th Annual Health Care Conference at the Boston Marriott Copley Place in Boston on Monday, March 7, 2016 at 4:40 p.m. ET.
A live webcast will be available on the investors section of the Company's website: www.scynexis.com. A replay of the presentation will be available approximately two hours after the event and will be available for two weeks following the presentation.
SCYNEXIS is a pharmaceutical company committed to the development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. We are developing our lead product candidate, SCY-078, as an oral and intravenous drug for the treatment of serious and life-threatening invasive fungal infections in humans. For more information, visit www.scynexis.com.
Last updated: Feb 29, 2016